The objective of the study was to assess factors associated with treatment satisfaction among patients receiving antihypertensive therapy. A weighted crosssectional online survey was conducted with hypertensive patients participating in a chronic disease panel in the US. Patients on monotherapy with medications from the following classes were identified: ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), beta blockers (BBs), calcium channel blockers (CCBs), and diuretics. The control group included patients without treatment. Pairwise comparisons between groups were conducted for factors that may affect patients' satisfaction. The study population had a mean age of 54.7714.2 years and was 56.7% female. Participants with blood pressure (BP) controlled to JNC 7 guidelines were more satisfied with their medication than those with uncontrolled BP (90.3 vs 71.5%, Po0.05). Patients who had not experienced adverse events had higher satisfaction than patients experiencing adverse events (90.9 vs 75.8%, Po0.05). The most frequently self-reported adverse events were frequent urination, sexual dysfunction, and fatigue ranging from 7.0 to 9.6% across classes. The adverse event rates differed by class and were lowest among the ARBs. Patients on ARBs were the most likely to have switched from a previous antihypertensive class as compared to other classes (57.1% ARBs vs 49.8% ACEIs, 38.7% diuretics, 36.3% CCBs, and 31.7% BBs). Physician recommendation was the most common reason for switching. In conclusion, the ability to effectively treat hypertension depends upon a patient's satisfaction with antihypertensive therapy, which may be improved by achieving BP control and minimizing the occurrence of adverse events.
Introduction
Approximately one in four persons in the United States (US) has hypertension, which is defined by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) as blood pressure (BP) greater than or equal to 140/90 mmHg. 1 Direct and indirect costs related to the treatment of hypertension are estimated to be $59.7 billion annually. 2 Opportunities to improve BP control exist. One study employing 'goal-oriented management' -treatment to achieve a specific blood pressure goal without a formal drug-treatment algorithm -found that only 63% of patients achieved the systolic blood pressure (SBP) goal, 86% achieved the diastolic blood pressure (DBP) goal, and 59% achieved both goals. 3 Analyses of the 1999-2000 National Health and Nutrition Examination Survey (NHANES) showed that while approximately 69% of adults over 18 years of age were aware of their hypertension and 58% were being treated, only 31% had their hypertension controlled. 4 Although the 2004 NCQA report stated that in 2003 58.6% of the Medicaid patients, 61.4% of the Medicare patients, and 62.2% of the commercially insured patients had controlled blood pressure defined by HEDIS guidelines, 5 there are opportunities for further improvement in BP control.
Poor BP control is related to patient adherence with their antihypertensive medication. The likelihood of adherence with a recommended regimen may be influenced by the patients' satisfaction with their medication. Unfortunately, little information exists regarding satisfaction with prescribed medications, the factors that influence satisfaction, and the relationship between medication satisfaction and adherence or persistence. Many of the prior studies were exploratory in nature, trying to identify a standardized structure for measuring satisfaction. [6] [7] [8] [9] [10] Most surveys that have been developed and validated are aimed at specific areas of care such as satisfaction with medical services, devices for medication administration, and routes of medication administration, but not satisfaction with medications. For example, studies have compared satisfaction with pharmacological vs nonpharmacological treatments for hypertension, oral vs topical vs implantation treatments for erectile dysfunction, inhalers for treatment of asthma, medical care received from health care providers, and surgical outcomes. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] None of the studies compared patient satisfaction achieved with different classes of medications for a chronic condition that requires long-term medication therapy.
The primary objective of this study was to investigate, at a general level, what factors influence satisfaction with antihypertensive therapy. The study focused on patients receiving monotherapy compared to no treatment in order to isolate the characteristics of individual drug classes and their impact on satisfaction with therapy.
Research design and methods

Study sample
This study used a web-based approach to survey patients from the Harris Interactive Service Bureau (HISB) Chronic Illness Panel (CIP). The CIP is a panel of patients recruited from various sources (eg, broadband connectors (150 000 þ ), individuals with health conditions (750 000 þ ), physicians (10 000 þ ), small business/home office workers (40 000 þ ), youth, and young adults (500 000 þ )) to ensure representation of the general population in the US. The incentive for the panel members to participate in a study is to accrue points that can be redeemed for goods and services. HISB manages and updates the CIP by systematic tracking of respondent behavior, obtaining feedback from respondents for every survey, and alternating incentive systems. The CIP includes approximately two million individuals; approximately 112 000 of these patients have a diagnosis of hypertension. Patients identified with hypertension were randomly selected to ensure variability in the sample frame.
Methods
The survey of patient satisfaction with antihypertensive therapy was conducted online during the month of October 2003. A pilot of the survey sample was employed to test the survey instrument for any potential measurement error. Respondents were qualified and selected with a screening survey if they reported a confirmed diagnosis of hypertension, were 18 years of age or older, and were receiving monotherapy with one of the following five classes of antihypertensive medications for at least 1 month: ACE inhibitors (ACEIs), angiotensin II receptor blockers (ARBs), beta blockers (BBs), calcium channel blockers (CCBs), or diuretics. In addition, respondents with hypertension who reported no current prescription antihypertensive usage at the time of the study were identified and included as a control group. In total, six groups of respondents with an equal distribution of 250 respondents in each group were screened and invited to participate in the full survey.
In order to adjust for any demographic biases resulting from online data collection, final survey data were weighted to reflect the demographics of the US adult population diagnosed with hypertension based on the 1999-2000 NHANES survey data. 21 NHANES surveys a nationally representative sample of adults who report being diagnosed with hypertension or high BP. As this sample is identified by door-to-door survey research, selection bias is greatly reduced when compared with on-line panel data collection. From the NHANES data set, demographic information was obtained for patients with hypertension who reported current medication use and separately for those respondents who were not medicating their condition. This information was used to weight the online survey data by gender, age, education, and race/ethnicity to match the demographic profile of the US adult population with hypertension.
Study measures
Demographics, comorbid conditions, and quality of life measured by the SF-12 were obtained from qualified respondents. Based on the Charlson Comorbidity Index (CCI), the list of comorbid conditons included: anemia, cancer, congestive heart failure (CHF), depression, diabetes, heart disease, high cholesterol, kidney disease, liver disease, lung disease, mental illness, osteoporosis, and ulcer. The prevalence of self-reported comorbid conditions were stratified by medication class.
The measures for medication satisfaction used in this study included: overall satisfaction with the current medication, likelihood of continuing treatment, and likelihood of recommending the treatment to family or friends with the condition. These questions were based on a seven-point Likert scale, where 1 represented least satisfaction or likelihood and 7 represented most satisfaction or likelihood. Satisfaction measures were compared between patients who had self-reported controlled BP (o140/90 mmHg or o130/80 mmHg for those with diabetes or chronic kidney disease) vs patients with uncontrolled blood pressure.
Although the purpose of this study was not to measure the rates of adverse events, the study solicited adverse events experienced among the study population to determine the influence of these events on patient satisfaction. It was assumed the patients' physician would be managing any adverse events. The list of adverse events included: blurred vision, constipation, cough, decreased heart rate, depression, dizziness, drowsiness, dry mouth, edema, fainting, flushing, weakness, frequent urina-tion, headache, hives/rash, increased heart rate, insomnia, fatigue, low BP, mood swing, nausea, nervousness, poor concentration, sexual dysfunction, stomach discomfort, and vomiting. The frequency of self-reported adverse events was stratified by medication class. Satisfaction measures were compared between patients who self-reported an adverse event vs those who did not.
Primary reasons for switching antihypertensive medications were requested from respondents who were previously treated with a different antihypertensive medication. Comparisons between groups were performed using w 2 tests for difference in proportions and analysis of variance (ANOVA) for difference in means.
Results E-mail invitations were sent to 51 186 panel members. A total of 8263 respondents from the on-line panel completed the screening section of the survey instrument (response rate of 16.1%). Of the 8263 respondents, 3160 were qualified based on age, current medication use, and hypertension diagnosis. Only the first 1500 were selected for the study because the sample size was sufficient for statistical analysis. The final data set was obtained from a total of 1508 qualified respondents with 229 respondents on BBs, 235 on diuretics, 241 on ARBs, 258 on ACEIs, 293 on CCBs, and 252 respondents not on any antihypertensive medication. The study population was 56.7% female. The mean age of the study population was 54.7714.2 years. Patients receiving CCBs were significantly older compared to patients in the other groups, while those not receiving any antihypertensive medication were significantly younger (Table 1) .
Respondents receiving ACEIs, CCBs, and ARBs had a higher average number of comorbid conditions than did those not receiving any antihypertensive therapy. Patients receiving CCBs had more comorbid conditions as compared to patients receiving diuretics (Po0.05) ( Table 1 ). In general, the study population had a low number of comorbid conditions. Approximately 6.1% of the overall population had a history of hospitalization and the percentage ranged from 2.5 to 8.4% among the treatment groups ( Table 1 ). The overall study population had a mean physical composite score (PCS) and a mean mental composite score (MCS) from the SF-12 survey similar to those of the normative data for hypertension (43.2712.1 vs 43.7710.3 for PCS and 49.5710.7 vs 49.179.5 for MCS). 22 Respondents' self-reported BPs showed that both SBP and DBP were higher before starting current antihypertensive therapy as compared to current SBP and DBP (Table 1) .
Patients with controlled BP had better overall satisfaction with their medications (Po0.001). In addition, these patients were more likely to continue their medication (Po0.001). However, the difference in likelihood to recommend their current medication to their friends and family was nonsignificant ( Figure 1) . Additionally, patients who did not experience adverse events had significantly higher overall satisfaction with their medication and were more likely to recommend their medication to their family and friends compared with those who had adverse events (Po0.001; Figure 2) .
The study found that the nine most frequently reported adverse events among the five antihypertensive-treated groups were constipation, cough, dizziness, drowsiness, fatigue, frequent urination, poor concentration, sexual dysfunction, and stomach discomfort. Some events were more frequently reported by patients on certain classes of treatments. For example, the diuretic group had the highest percentages of frequent urination and constipation; the ACEI group coughing; the BB group dizziness, fatigue, drowsiness, and stomach discomfort; and the CCB group poor concentration (Table 2) . Overall, the diuretic group had the highest adverse event rate, while the ARB group had the lowest rate (Table 2) .
Patients receiving ARBs had the highest percentage of patients who previously used other antihypertensive medications (Figure 3) . The most common reason reported for switching antihypertensive therapy were physician's recommendation, followed by adverse events experienced with previous treatment, efficacy, and cost. Physician's recommendation was the primary reason for switching in all groups except diuretics. Among patients who switched to diuretics, the number of patients who switched medication due to physician's recommendation was approximately equal to the number who switched due to lack of efficacy of prior treatment (Figure 4) . Patients who discontinued their prior medication due to adverse events were most likely to switch to the ARBs (Figure 4) .
Discussion
This patient-reported outcome study provides evidence from a naturalistic setting that patients have higher satisfaction with their antihypertensive medication if their BP control is improved and their medication has minimal side effects. Since there are many antihypertensive medications available on the market with comparable efficacy, the ability to effectively treat hypertension depends on patient adherence to the medication. This, in turn, depends upon the patient's satisfaction with the prescribed regimen. The current medical literature on patient satisfaction with antihypertensive therapy is limited. To address this gap, this study surveyed a group of patients with hypertension and found that a significantly higher percentage of patients with controlled BP expressed satisfaction with their medication compared to those with uncontrolled Patient satisfaction with antihypertensive therapy K Chen et al Certain adverse events are more likely to be associated with specific antihypertensive classes. For example, diuretics are associated with frequent urination and hyperglycemia, loop diuretics with hypokalemia, BBs with withdrawal syndrome such as tachycardia, and ACEI with cough. Not all of the reported adverse events in this study population coincided with the results reported in clinical trials; for example, while sexual dysfunction has not been commonly reported among patients taking ACEIs in prior clinical trials, it was the most frequently reported adverse event found among patients who used ACE inhibitors in this study. 23 This observation can be due to various factors associated with surveying patients in a naturalistic setting. The purpose of our study was not to measure the adverse event rates. However, the study did suggest that there are differences in adverse events across different antihypertensive medication classes, and that those adverse events can affect patients' satisfaction with treatment.
Many factors influence the decision to switch antihypertensive treatments. Physicians' recommendations and patients' experience with adverse events associated with medication were the top two reasons reported in this study. Physicians should consider the adverse events commonly associated with various medications when prescribing the treatment to their patients as some patients may be nonadherent should intolerable adverse events occur. Patients should monitor for common adverse events when starting a new medication to achieve higher treatment satisfaction and to reduce the risk of nonadherence or discontinuation of the treatment. In addition, physicians should take into consideration the confounding effect resulting from the similarity of symptoms between a patient's underlying comorbid condition and the adverse events caused by the prescribed medication. For example, a patient may complain of edema, which could be either a symptom of heart failure or an adverse event associated with ACEIs. Extra monitoring may be required for physicians when they prescribe antihypertensive medications to patients with comorbid conditions. Our study did not have an objective measure of medication compliance and no quantitative connection can be made between adverse events, satisfaction, and persistence. Finding this connection remains an objective for further research. However, it is very plausible that satisfaction with a given therapy would have an impact on persistence. Since satisfaction is related to the occurrence of adverse events, physicians may want to carefully monitor these events and adjust therapy accordingly. This study observed that among the five drugtreated groups, patients receiving ARBs had the highest percentage of patients who previously used other antihypertensive therapies. It is possible that patients switched drugs due to adverse events or inadequate BP control associated with the previous drug.
Limitations
Several limitations should be noted. First, the use of the CIP and online administration may present a bias by selecting a sample population with more education and higher socioeconomic status compared with the general population. However, we weighted our study to resemble the broader population based upon patient characteristics from the NHANES population survey. 21 The SF-12 PCS and MCS scores from the survey demonstrated the similarity of the study population in terms of health-related quality of life. We believe this study population was representative of the general adult population of interest in the US and provides evidence that these findings can be generalized to that of the greater population.
Second, although all respondents were on monotherapy due to the selection criteria, the disease severity level may have varied between patients. Patients receiving CCBs had more comorbid heart disease, and those on ARBs had more heart failure, diabetes, and kidney disease. The direction of this potential bias with respect to medication satisfaction is not certain. In addition, the study might have selected patients whose BPs were not well controlled because they required multiple-regimen therapy rather than the monotherapy they were receiving. The effect of this factor on the study results is also unknown.
Third, while the study primarily focused on the association of efficacy, adverse event profiles and treatment satisfaction, other factors may affect patient satisfaction with antihypertensive therapy. For instance, previous studies have shown a positive association between medication adherence and the physician-patient relationship. 24 Owing to constraints in the length of the survey our study did not investigate this aspect.
The response rate of this study was relatively low compared with response rates obtained in other web-based survey studies. 25, 26 One of the concerns over this low response rate was the selection bias of patients who responded to the invitation. However, we employed a controlled replicative process for the distribution of the sample pool to insure that response rates would have minimal impact on the validity of the final data set. Furthermore, because the final data set was very similar to the NHANES data, it can be concluded that nonresponse rates did not have an effect on the error rates within the survey.
Finally, since the study data were self-reported survey results, the likelihood of patient-recall bias and reporting errors should not be disregarded.
Conclusions
Hypertension is an asymptomatic and chronic illness. Perfect adherence with medication is difficult to achieve. Satisfaction with treatment can be among the many factors that influence adherence. Further research is needed to examine the relationship between satisfaction with treatment and patient adherence with medication, which may impact BP control. Successful control of BP can reduce cardiovascular events only if patients continue to take their medication as prescribed. Poor BP control rates seen in prior studies may be improved by understanding the differences in antihypertensive medications, choosing the most appropriate therapy, monitoring for potential adverse events, and intervening as needed. 
